Bempedoic Acid also lowers inflammation which could be a huge benefit as well. Same Lipid Experts behind Lipitor (Dr Roger Newton) is behind ETC-1002. I follow AniuStudent on Twitter who has been dead on with this stock. He seems to know a lot about the upside and risks and likes his chances with ESPR. Pfizer has probably nearly 20Bil in cash and cash equivalents. Esperion states that 181 Million People in the US, Europe, and Japan suffer from High LDL-C. At 3,000 a year, it doesnt take much Market share to have a huge winner. 10% of 40Mil Patients with High LDL-C are Statin Intolerent. That market alone is worth Pfizer paying Esperion $4Bil, if Esperion would sell it for that. Drug has a clear path to market and could see $100+ in 2 years with No Buyout. I personally think History is about to repeat itself with Esperion and Pfizer. All the best to all the Longs. Was a good day today. :-D
News 
Market Data 
Discover 
